These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30594446)

  • 1. Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma.
    Bond DA; Dotson E; Awan FT; Baiocchi RA; Blum KA; Maddocks K
    Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):e123-e128. PubMed ID: 30594446
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma.
    Cencini E; Fabbri A; Bocchia M
    Br J Haematol; 2017 Mar; 176(5):831-833. PubMed ID: 26913966
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment Strategies for Advanced Classical Hodgkin Lymphoma in the Times of Dacarbazine Shortage.
    Torka P; Przespolewski E; Evens AM
    JCO Oncol Pract; 2022 Jul; 18(7):491-497. PubMed ID: 35254922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab-ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy.
    Garciaz S; Harel S; Amorim S; Bouabdallah R; Thieblemont C; Brice P
    Br J Haematol; 2016 Nov; 175(4):735-737. PubMed ID: 26685097
    [No Abstract]   [Full Text] [Related]  

  • 5. PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial.
    Pavlovsky A; Fernandez I; Kurgansky N; Prates V; Zoppegno L; Negri P; Milone G; Cerutti I; Zabaljauregui S; Mariano R; Grecco HF; Basquiera AL; Saba S; Rudoy S; Sackmann F; Castano V; Remaggi G; Cabrejo M; Roveri E; Casale MF; Cabane V; Taus R; Venturini C; Sakamoto F; Varela AI; Riddick M; Pavlovsky S;
    Br J Haematol; 2019 Jun; 185(5):865-873. PubMed ID: 30864146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study.
    Hutchings M; Radford J; Ansell SM; Illés Á; Sureda A; Connors JM; Sýkorová A; Shibayama H; Abramson JS; Chua NS; Friedberg JW; Kořen J; LaCasce AS; Molina L; Engley G; Fenton K; Jolin H; Liu R; Gautam A; Gallamini A
    Hematol Oncol; 2021 Apr; 39(2):185-195. PubMed ID: 33462822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.
    Chand VK; Link BK; Ritchie JM; Shannon M; Wooldridge JE
    Leuk Lymphoma; 2006 Apr; 47(4):657-63. PubMed ID: 16690524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly.
    Stamatoullas A; Brice P; Bouabdallah R; Mareschal S; Camus V; Rahal I; Franchi P; Lanic H; Tilly H
    Br J Haematol; 2015 Jul; 170(2):179-84. PubMed ID: 25891777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen?
    Canellos GP; Duggan D; Johnson J; Niedzwiecki D
    J Clin Oncol; 2004 Apr; 22(8):1532-3. PubMed ID: 15084636
    [No Abstract]   [Full Text] [Related]  

  • 10. Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma.
    D'Arco AM; Califano C; Barone L; Belsito Petrizzi V; Iovino V; Langella M; Maglione V; Rivellini F; De Lorenzo S
    Br J Haematol; 2015 Nov; 171(4):662-5. PubMed ID: 25873239
    [No Abstract]   [Full Text] [Related]  

  • 11. Autoimmune hemolytic anemia and classical Hodgkin lymphoma: a case report and literature review.
    Feng Q; Zak D; Daya R
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):270-6. PubMed ID: 22706493
    [No Abstract]   [Full Text] [Related]  

  • 12. ABVD plus rituximab
    Strati P; Fanale MA; Oki Y; Turturro F; Fayad LE; Bartlett NL; Gladstone DE; Kasamon YL; Portlock CS; Wilson WH; Goy A; Younes A; Lee HJ
    Haematologica; 2019 Feb; 104(2):e65-e67. PubMed ID: 30190343
    [No Abstract]   [Full Text] [Related]  

  • 13. Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis.
    Graczyk J; Cheung MC; Buckstein R; Chan K
    Leuk Lymphoma; 2014 Jan; 55(1):56-62. PubMed ID: 23597142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bilateral sudden hearing loss following ABVD protocol.
    Tazi I; Nafil H; Mahmal L
    J Cancer Res Ther; 2014; 10(1):212. PubMed ID: 24762521
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
    Ogura M; Itoh K; Ishizawa K; Kobayashi Y; Tobinai K; Kinoshita T; Hirano M; Ueda R; Shibata T; Nakamura S; Tsukasaki K; Hotta T; Shimoyama M; Morishima Y;
    Leuk Lymphoma; 2013 Jan; 54(1):46-52. PubMed ID: 22712838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced Hodgkin's disease: ABVD is better, yet is not good enough!
    Diehl V
    J Clin Oncol; 2003 Feb; 21(4):583-5. PubMed ID: 12586791
    [No Abstract]   [Full Text] [Related]  

  • 17. Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation.
    Arakelyan N; Jais JP; Tomowiack C; Colombat P; Berthou C; Desablens B; Moles-Moreau MP; Gastinne T; Quittet P; Casassus P; Le Pourhiet-Le Mevel A; Ghandour C; Brière J; Colonna P; Andrieu JM
    Leuk Lymphoma; 2013 Jan; 54(1):76-82. PubMed ID: 22680774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial.
    Arakelyan N; Jais JP; Delwail V; Brière J; Moles-Moreau MP; Sénécal D; Berthou C; Desablens B; Colonna P; Andrieu JM;
    Cancer; 2010 Sep; 116(17):4054-62. PubMed ID: 20564152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced Lymphocyte-rich Classical Hodgkin Lymphoma Complicated with Fatal Hemophagocytic Syndrome.
    Ichikawa S; Takahashi T; Katsushima H; Fukuhara N; Ichinohasama R; Harigae H
    Intern Med; 2016; 55(2):191-6. PubMed ID: 26781022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
    J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.